166 related articles for article (PubMed ID: 35845542)
1. Comparison of the efficacy and safety of caplacizumab versus placebo in thrombotic thrombocytopenic purpura: a meta-analysis and systematic review based on randomized controlled trials.
Chen B; Li X; Xiao D; Raimundo RD; Zhou R; Lei Y
Ann Transl Med; 2022 Jun; 10(12):657. PubMed ID: 35845542
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
He J; Qi J; Han H; Xu X; Li X; Song X; Han Y
Expert Rev Hematol; 2023 May; 16(5):377-385. PubMed ID: 37045600
[TBL] [Abstract][Full Text] [Related]
3. Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
Djulbegovic M; Tong J; Xu A; Yang J; Chen Y; Cuker A; Pishko AM
Blood Adv; 2023 May; 7(10):2132-2142. PubMed ID: 36053773
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
Peng JY; Wang SY; Chen MQ; Liu CX; Zhao YT; Xu TS; Wu QL
Blood Coagul Fibrinolysis; 2024 Jun; ():. PubMed ID: 38874905
[TBL] [Abstract][Full Text] [Related]
5. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
Hollifield AL; Arnall JR; Moore DC
Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
[TBL] [Abstract][Full Text] [Related]
6. Does Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse, exacerbation, and bleeding? An updated systematic review and meta-analysis based on revised criteria by the International Working Group for thrombotic thrombocytopenic purpura.
Neupane N; Thapa S; Mahmoud A; Bhattarai A; Kc A; Shikhrakar S; Gurusinghe S; Kuiodes P
EJHaem; 2024 Feb; 5(1):178-190. PubMed ID: 38406548
[TBL] [Abstract][Full Text] [Related]
7. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience with caplacizumab in the management of acute TTP.
Dutt T; Shaw RJ; Stubbs M; Yong J; Bailiff B; Cranfield T; Crowley MP; Desborough M; Eyre TA; Gooding R; Grainger J; Hanley J; Haughton J; Hermans J; Hill Q; Humphrey L; Lowe G; Lyall H; Mohsin M; Nicolson PLR; Priddee N; Rampotas A; Rayment R; Rhodes S; Taylor A; Thomas W; Tomkins O; Van Veen JJ; Lane S; Toh CH; Scully M
Blood; 2021 Apr; 137(13):1731-1740. PubMed ID: 33150355
[TBL] [Abstract][Full Text] [Related]
9. Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab.
Mellaza C; Henry N; Fayolle PM; Mortaza S; Subra JF; Veyradier A; Coppo P; Augusto JF
Front Med (Lausanne); 2020; 7():549931. PubMed ID: 33195299
[TBL] [Abstract][Full Text] [Related]
10. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic plasma exchange-free treatment for first-episode TTP: A systematic review.
Wang J; Cheng F; Niu Y; Yan L; Li J; Tan B; Qin L
Transfus Apher Sci; 2023 Jun; 62(3):103661. PubMed ID: 36878741
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
[TBL] [Abstract][Full Text] [Related]
13. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.
Peyvandi F; Cataland S; Scully M; Coppo P; Knoebl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Minkue Mi Edou J; De Winter H; Callewaert F
Blood Adv; 2021 Apr; 5(8):2137-2141. PubMed ID: 33881463
[TBL] [Abstract][Full Text] [Related]
14. Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data.
Gavriilaki E; Nikolousis E; Koravou EE; Dimou-Besikli S; Kartsios C; Papakonstantinou A; Mpanti A; Pontikoglou C; Kalpadaki C; Bitsani A; Tassi I; Touloumenidou T; Chatziconstantinou T; Papathanasiou M; Syrigou A; Ztriva E; Kaiafa G; Mandala E; Mellios Z; Karakasis D; Kourakli A; Symeonidis A; Kapsali E; Papadaki HH; Lalayanni C; Sakellari I
Front Med (Lausanne); 2023; 10():1226114. PubMed ID: 37901415
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.
Izquierdo CP; Mingot-Castellano ME; Fuentes AEK; García-Arroba Peinado J; Cid J; Jimenez MM; Valcarcel D; Gómez-Seguí I; de la Rubia J; Martin P; Goterris R; Hernández L; Tallón I; Varea S; Fernández M; García-Muñoz N; Vara M; Zarzoso MF; García-Candel F; Paciello ML; García-García I; Zalba S; Campuzano V; Gala JM; Estévez JV; Jiménez GM; López Lorenzo JL; Arias EG; Freiría C; Solé M; Ávila Idrovo LF; Hernández Castellet JC; Cruz N; Lavilla E; Pérez-Montaña A; Atucha JA; Moreno Beltrán ME; Moreno Macías JR; Salinas R; Del Rio-Garma J
Blood Adv; 2022 Dec; 6(24):6219-6227. PubMed ID: 35930694
[TBL] [Abstract][Full Text] [Related]
16. Real-world data of the use and experience of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: Case series.
Albanell-Fernández M; Monge-Escartín I; Carcelero-San Martín E; Riu Viladoms G; Ruiz-Boy S; Lozano M; Soy D; Moreno-Castaño AB; Diaz-Ricart M; Cid J
Transfus Apher Sci; 2023 Jun; 62(3):103722. PubMed ID: 37169697
[TBL] [Abstract][Full Text] [Related]
17. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials.
Michael M; Elliott EJ; Craig JC; Ridley G; Hodson EM
Am J Kidney Dis; 2009 Feb; 53(2):259-72. PubMed ID: 18950913
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.
Scully M; de la Rubia J; Pavenski K; Metjian A; Knöbl P; Peyvandi F; Cataland S; Coppo P; Kremer Hovinga JA; Minkue Mi Edou J; De Passos Sousa R; Callewaert F; Gunawardena S; Lin J
J Thromb Haemost; 2022 Dec; 20(12):2810-2822. PubMed ID: 36138517
[TBL] [Abstract][Full Text] [Related]
19. Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry.
Agosti P; De Leo P; Capecchi M; Ferrari B; Mancini I; Gattillo S; Trisolini SM; Rinaldi E; Podda GM; Prezioso L; Salutari P; Facchini L; Caramazza D; Tolomelli G; Artoni A; Peyvandi F
Res Pract Thromb Haemost; 2023 Aug; 7(6):102185. PubMed ID: 37720483
[TBL] [Abstract][Full Text] [Related]
20. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial).
Estcourt LJ
Transfus Med; 2019 Jun; 29(3):146-148. PubMed ID: 31318128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
